Auriga Reiterates a 'Buy' on eResearch Technology (ERT); Growth at a Value Price
Tweet Send to a FriendGet Alerts ERT Hot Sheet
Price: $7.98 --0%
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade ERT Now!
Auriga reiterates a 'Buy' on eResearch Technology (NASDAQ: ERT), PT $10.
Auriga analyst says, "Our checks from the recent Drug Information Association (DIA) conference and meeting with management confirms our view that ERT is an attractive and modest (high single digit) growth story trading at a value multiple. With last summer's acquisition of Carefusion's (NYSE: CFN)(NotRated) Research Services division (RS), and recent traction with its ePRO offerings, the Company has wisely diversified its business lines beyond a pure cardiac safety testing provider. Our conversations with newly appointed CEO Jeff Litwin, MD, and CFO Keith Schneck, lead us to believe that performance in the back half of FY11 and FY12 will demonstrate a return to growth with margin expansion as the synergies of the merger take hold. We recommend buying the stock at current levels."
"Based on our new growth assumptions for ERT's business lines, we are increasing our FY12 EPS and revenue estimates very modestly, by $0.01 and $500,000, respectively."
For more ratings news on eResearch Technology click here and for the rating history of eResearch Technology click here.
Shares of eResearch Technology closed at $6.40 yesterday, with a 52 week range of $5.43-$7.12.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Auriga analyst says, "Our checks from the recent Drug Information Association (DIA) conference and meeting with management confirms our view that ERT is an attractive and modest (high single digit) growth story trading at a value multiple. With last summer's acquisition of Carefusion's (NYSE: CFN)(NotRated) Research Services division (RS), and recent traction with its ePRO offerings, the Company has wisely diversified its business lines beyond a pure cardiac safety testing provider. Our conversations with newly appointed CEO Jeff Litwin, MD, and CFO Keith Schneck, lead us to believe that performance in the back half of FY11 and FY12 will demonstrate a return to growth with margin expansion as the synergies of the merger take hold. We recommend buying the stock at current levels."
"Based on our new growth assumptions for ERT's business lines, we are increasing our FY12 EPS and revenue estimates very modestly, by $0.01 and $500,000, respectively."
For more ratings news on eResearch Technology click here and for the rating history of eResearch Technology click here.
Shares of eResearch Technology closed at $6.40 yesterday, with a 52 week range of $5.43-$7.12.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Wedbush Downgrades salesforce.com (CRM) to Neutral
- Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1
- Deutsche Bank Resumes CenterPoint Energy (CNP) at Hold
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Auriga
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
